Literature DB >> 7621074

Targeted disruption of the flk2/flt3 gene leads to deficiencies in primitive hematopoietic progenitors.

K Mackarehtschian1, J D Hardin, K A Moore, S Boast, S P Goff, I R Lemischka.   

Abstract

The flk2 receptor tyrosine kinase has been implicated in hematopoietic development. Mice deficient in flk2 were generated. Mutants developed into healthy adults with normal mature hematopoietic populations. However, they possessed specific deficiencies in primitive B lymphoid progenitors. Bone marrow transplantation experiments revealed a further deficiency in T cell and myeloid reconstitution by mutant stem cells. Mice deficient for both c-kit and flk2 exhibited a more severe phenotype characterized by large overall decreases in hematopoietic cell numbers, further reductions in the relative frequencies of lymphoid progenitors, and a postnatal lethality. Taken together, the data suggest that flk2 plays a role both in multipotent stem cells and in lymphoid differentiation.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7621074     DOI: 10.1016/1074-7613(95)90167-1

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  143 in total

1.  Preclinical efficacy of MEK inhibition in Nras-mutant AML.

Authors:  Michael R Burgess; Eugene Hwang; Ari J Firestone; Tannie Huang; Jin Xu; Johannes Zuber; Natacha Bohin; Tiffany Wen; Scott C Kogan; Kevin M Haigis; Deepak Sampath; Scott Lowe; Kevin Shannon; Qing Li
Journal:  Blood       Date:  2014-10-31       Impact factor: 22.113

Review 2.  Optimizing hematopoietic stem cell engraftment: a novel role for thrombopoietin.

Authors:  Catherine M Verfaillie
Journal:  J Clin Invest       Date:  2002-08       Impact factor: 14.808

3.  Functional specialization of islet dendritic cell subsets.

Authors:  Na Yin; Jiangnan Xu; Florent Ginhoux; Gwendalyn J Randolph; Miriam Merad; Yaozhong Ding; Jonathan S Bromberg
Journal:  J Immunol       Date:  2012-04-16       Impact factor: 5.422

Review 4.  FLT3 inhibitors in AML: are we there yet?

Authors:  Akshay Sudhindra; Catherine Choy Smith
Journal:  Curr Hematol Malig Rep       Date:  2014-06       Impact factor: 3.952

5.  Fell Pony syndrome: characterization of developmental hematopoiesis failure and associated gene expression profiles.

Authors:  Rebecca L Tallmadge; Tracy Stokol; Mary Jean Gould-Earley; Ed Earley; Erica J Secor; Mary Beth Matychak; M Julia B Felippe
Journal:  Clin Vaccine Immunol       Date:  2012-05-16

Review 6.  Contingent gene regulatory networks and B cell fate specification.

Authors:  Harinder Singh; Kay L Medina; Jagan M R Pongubala
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-23       Impact factor: 11.205

Review 7.  FLT3 antibody-based therapeutics for leukemia therapy.

Authors:  Yiwen Li; Zhenping Zhu
Journal:  Int J Hematol       Date:  2005-08       Impact factor: 2.490

8.  Meis1 programs transcription of FLT3 and cancer stem cell character, using a mechanism that requires interaction with Pbx and a novel function of the Meis1 C-terminus.

Authors:  Gang G Wang; Martina P Pasillas; Mark P Kamps
Journal:  Blood       Date:  2005-03-08       Impact factor: 22.113

Review 9.  Incorporating FLT3 inhibitors into acute myeloid leukemia treatment regimens.

Authors:  Keith Pratz; Mark Levis
Journal:  Leuk Lymphoma       Date:  2008-05

10.  RNA interference screen in primary human T cells reveals FLT3 as a modulator of IL-10 levels.

Authors:  Anne L Astier; Gaëlle Beriou; Thomas M Eisenhaure; Stephen M Anderton; David A Hafler; Nir Hacohen
Journal:  J Immunol       Date:  2009-12-16       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.